{
    "sec_cik": "0001136869",
    "sec_company_name": "ZIMMER BIOMET HOLDINGS, INC. (Filer)",
    "document_type": "EX991",
    "sec_form_header": "Form 8-K",
    "sec_period_of_report": "20220207",
    "sec_filing_date": "20220207",
    "sec_changed_date": "20220207",
    "sec_accepted_date": "20220207092646",
    "sec_index_url": "https://www.sec.gov//Archives/edgar/data/1136869/000119312522029163/0001193125-22-029163-index.htm",
    "sec_url": "https://www.sec.gov//Archives/edgar/data/1136869/000119312522029163/0001193125-22-029163.txt",
    "metadata_file_name": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0011\001\ZBH_0001136869_EX991_20220207_EX-99_metadata.json",
    "original_file_name": "",
    "original_file_size": "91261 chars",
    "document_group": "EX-99",
    "section_name": "EX-99",
    "section_n_characters": 56178,
    "endpoints": [
        "EX-99.1   ",
        "Reconciliation of Adjusted EBITDA (in $ millions) 3Q21 YTD 2019A 2020A (unaudited) Net loss of the Spine and Dental Businesses of Zimmer Biomet Holdings, Inc. ($28.0) ($179.1) ($34.6) Interest expense, net 0.1 0.3 0.3 (Benefit) provision for income taxes 0.2 (42.3) (1.3) Depreciation and amortization 135.1 134.3 95.7 EBITDA $107.4 ($86.8) $60.1 Share-based compensation[1] 10.7 10.2 8.8 Goodwill impairment[2] 142.0 Restructuring[3] 1.8 9.7 2.3 Acquisition, integration, divestiture and related[3] 3.2 2.2 12.0 Other various costs[4] 15.5 12.1 16.3 Adjusted EBITDA $138.6 $89.4 $99.5 [1] Excludes share-based compensation from Adjusted EBITDA due to its non-cash nature. [2] Excludes goodwill impairment from Adjusted EBITDA because of the significance of these charges and their non-cash nature. [3] Restructuring, acquisition, integration, divestiture and related costs are expenses from our Parent’s corporate restructuring program and from acquisitions and related integration that are directly related to the Company and are for a specified period of time. Therefore, we exclude these costs from Adjusted EBITDA. [4] Excludes certain Parent-related allocated expenses from projects, events or other various costs that are considered highly variable and for a specified period of time. These costs include expenses and gains from initial compliance with the EU Medical Device Regulation for previously-approved products, compliance with Parent’s deferred prosecution agreement related to certain US Foreign Corrupt Practices Act matters, allocation of costs from Parent’s global restructuring program, allocation of costs related to Parent’s integration activities of acquired businesses, and the impact from excess and obsolete inventory on certain product lines we intend to discontinue."
    ],
    "extraction_method": "html",
    "warnings": [],
    "company_description": "ZBH",
    "output_file": "C:\Users\aaron\OneDrive\Desktop\homework\finance2\SEC-EDGAR-text\output_files_examples\batch_0011\001\ZBH_0001136869_EX991_20220207_EX-99_excerpt.txt",
    "time_elapsed": 0.0,
    "batch_number": 11,
    "batch_signature": "",
    "batch_start_time": "2023-04-17 00:20:00.439699",
    "batch_machine_id": "DESKTOP-BTCJU5K",
    "section_end_time": "2023-04-17 00:22:45.705135"
}